Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 1
1999 2
2000 1
2002 3
2004 2
2005 2
2006 1
2007 2
2015 1
2017 1
2019 1
2020 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID- 19: A Randomized Controlled Trial.
Saeedi-Boroujeni A, Nashibi R, Ghadiri AA, Nakajima M, Salmanzadeh S, Mahmoudian-Sani MR, Hanafi MG, Sharhani A, Khodadadi A. Saeedi-Boroujeni A, et al. Arch Med Res. 2022 Jun;53(4):368-377. doi: 10.1016/j.arcmed.2022.03.002. Epub 2022 Mar 14. Arch Med Res. 2022. PMID: 35339280 Free PMC article. Clinical Trial.
BACKGROUND: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve progressive inflammation due to COVID-19. ...Long hospitalization (four days or above) was 36.6% in the Tranilast and 66.6% in the control group (RR = 0.58; 95% CI: 0.38-1.06, p = 0.0 …
BACKGROUND: Tranilast is a potential NLRP3 inflammasome inhibitor that may relieve progressive inflammation due to COVID-19. ...Long …
Preoperative tranilast as adjunctive therapy to primary pterygium surgery with a 1-year follow-up.
Almeida Junior GC, Arakawa L, Santi Neto Dd, Cury PM, Lima Filho AA, Sousa SJ, Alves MR, Azoubel R. Almeida Junior GC, et al. Arq Bras Oftalmol. 2015 Jan-Feb;78(1):1-5. doi: 10.5935/0004-2749.20150002. Arq Bras Oftalmol. 2015. PMID: 25714528 Free article. Clinical Trial.
PURPOSE: To determine the efficacy of tranilast as an adjunctive therapy in conjunctival autograft. METHODS: Twenty-nine patients were randomly allocated to the Tranilast Group (n=15) or the Control Group (n=14). The Tranilast Group received a subconjunctival …
PURPOSE: To determine the efficacy of tranilast as an adjunctive therapy in conjunctival autograft. METHODS: Twenty-nine patients wer …
The combined effect of tranilast 8% liposomal gel on the final cosmesis of acne scarring in patients concomitantly treated by isotretinoin: prospective, double-blind, split-face study.
Weinstein A, Koren A, Sprecher E, Zur E, Mehrabi JN, Artzi O. Weinstein A, et al. Clin Exp Dermatol. 2020 Jan;45(1):41-47. doi: 10.1111/ced.14032. Epub 2019 Aug 8. Clin Exp Dermatol. 2020. PMID: 31260124 Clinical Trial.
BACKGROUND: Tranilast [N-(3,4-dimethoxycinnamoyl) anthranilic acid] has never been investigated for the prevention and treatment of acne scars. AIM: To evaluate the efficacy and safety of tranilast 8% gel in improving the final appearance of patients with acne scarr …
BACKGROUND: Tranilast [N-(3,4-dimethoxycinnamoyl) anthranilic acid] has never been investigated for the prevention and treatment of a …
Effects of tranilast on filtering blebs: a pilot study.
Chihara E, Dong J, Ochiai H, Hamada S. Chihara E, et al. J Glaucoma. 2002 Apr;11(2):127-33. doi: 10.1097/00061198-200204000-00008. J Glaucoma. 2002. PMID: 11912360 Clinical Trial.
PURPOSE: To investigate the effects of topical instillation of 0.5% tranilast eye drops on intraocular pressure (IOP) and bleb formation after glaucoma filtering surgery. ...The bleb was significantly larger at 6 and 12 months (P = 0.024 and P = 0.049, respectively), and r …
PURPOSE: To investigate the effects of topical instillation of 0.5% tranilast eye drops on intraocular pressure (IOP) and bleb format …
The Effect of Tranilast 8% Liposomal Gel Versus Placebo on Post-Cesarean Surgical Scars: A Prospective Double-Blind Split-Scar Study.
Kohavi L, Sprecher E, Zur E, Artzi O. Kohavi L, et al. Dermatol Surg. 2017 Sep;43(9):1157-1163. doi: 10.1097/DSS.0000000000001140. Dermatol Surg. 2017. PMID: 28825957 Clinical Trial.
METHODS: In this prospective double-blind split-scar study, the authors treated each half scar of 26 women with either tranilast 8% liposomal gel or tranilast-free liposomal gel (placebo). ...The women were significantly more satisfied with the tranilast-trea …
METHODS: In this prospective double-blind split-scar study, the authors treated each half scar of 26 women with either tranilast 8% l …
Effect of tranilast in early-stage diabetic nephropathy.
Soma J, Sato K, Saito H, Tsuchiya Y. Soma J, et al. Nephrol Dial Transplant. 2006 Oct;21(10):2795-9. doi: 10.1093/ndt/gfl325. Epub 2006 Jul 4. Nephrol Dial Transplant. 2006. PMID: 16820373 Clinical Trial.
BACKGROUND: Tranilast is an antifibrotic drug known to suppress collagen synthesis by fibroblasts by interfering with the effects of TGF-beta. ...The changes of both U-A and U-IV excretions in the two groups took statistically different trends through tranilast trea …
BACKGROUND: Tranilast is an antifibrotic drug known to suppress collagen synthesis by fibroblasts by interfering with the effects of …
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.
Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M. Holmes DR Jr, et al. Circulation. 2002 Sep 3;106(10):1243-50. doi: 10.1161/01.cir.0000028335.31300.da. Circulation. 2002. PMID: 12208800 Free article. Clinical Trial.
Plaque volume was not different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm(3), respectively; P=0.16 to 0.72). CONCLUSIONS: Tranilast does not improve the quantitative measures of restenosis (angiographic and intravascular ultrasound) or it …
Plaque volume was not different between the placebo and tranilast groups (39.3 versus 37.5 to 46.1 mm(3), respectively; P=0.16 to 0.7 …
Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT).
Tamai H, Katoh O, Suzuki S, Fujii K, Aizawa T, Takase Si, Kurogane H, Nishikawa H, Sone T, Sakai K, Suzuki T. Tamai H, et al. Am Heart J. 1999 Nov;138(5 Pt 1):968-75. doi: 10.1016/s0002-8703(99)70025-6. Am Heart J. 1999. PMID: 10539831 Clinical Trial.
The restenosis rates defined as >/=50% loss of the initial gain were 14.7% in the 600 mg/d tranilast group, 35.2% in the 300 mg/d tranilast group, and 46.5% in the placebo group (P <. 0001 for 600 mg/d tranilast vs placebo). The restenosis rates defined …
The restenosis rates defined as >/=50% loss of the initial gain were 14.7% in the 600 mg/d tranilast group, 35.2% in the 300 mg/d …
The PRESTO (Prevention of restenosis with tranilast and its outcomes) protocol: a double-blind, placebo-controlled trial.
Holmes D, Fitzgerald P, Goldberg S, LaBlanche Jm, Lincoff AM, Savage M, Serruys PW, Willerson J, Granett JR, Chan R, Shusterman NH, Poland M. Holmes D, et al. Am Heart J. 2000 Jan;139(1 Pt 1):23-31. doi: 10.1016/s0002-8703(00)90304-1. Am Heart J. 2000. PMID: 10618558 Clinical Trial.
BACKGROUND: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coronary revascularization (PTCR). Tranilast interferes with proliferation and migration of vascular medial smooth muscle cells induced by …
BACKGROUND: Tranilast is a unique drug in clinical development for the prevention of restenosis after percutaneous transluminal coron …
Effect of tranilast eyedrops in preventing posterior capsule opacification: preliminary report.
Tobari I, Iwaki Y, Miyake K. Tobari I, et al. J Cataract Refract Surg. 1999 Oct;25(10):1394-9. doi: 10.1016/s0886-3350(99)00211-4. J Cataract Refract Surg. 1999. PMID: 10511942 Clinical Trial.
PURPOSE: To evaluate the effect of tranilast eyedrops in preventing fibrous opacification of the posterior lens capsule after cataract extraction and intraocular lens (IOL) implantation. ...There was a significant difference in the 1 and 3 month findings between the 2 grou …
PURPOSE: To evaluate the effect of tranilast eyedrops in preventing fibrous opacification of the posterior lens capsule after catarac …
22 results

Searches related to "tranilast"